Table of Contents Author Guidelines Submit a Manuscript
Dermatology Research and Practice
Volume 2014, Article ID 953597, 5 pages
http://dx.doi.org/10.1155/2014/953597
Research Article

IL-1RN VNTR Polymorphism in Adult Dermatomyositis and Systemic Lupus Erythematosus

1Molecular Medicine Center and Department of Medical Chemistry and Biochemistry, Medical University-Sofia, 2 Zdrave Street, 1431 Sofia, Bulgaria
2Department of Clinical Laboratory and Clinical Immunology and Department of Nephrology, Medical University-Sofia, 1 Georgi Sofijski Street, 1431 Sofia, Bulgaria
3National Genetic Laboratory, Maichin Dom Hospital, 2 Zdrave Street, 1431 Sofia, Bulgaria
428 Diagnostic and Consultative Center-Sofia, 1 Iliya Beshkov Street, 1592 Sofia, Bulgaria
5Department of Dermatology and Venereology, Medical University-Sofia, 1 Georgi Sofijski Street, 1431 Sofia, Bulgaria

Received 14 June 2014; Accepted 7 August 2014; Published 19 August 2014

Academic Editor: Elizabeth Helen Kemp

Copyright © 2014 Zornitsa Kamenarska et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. J. O'Shea, A. Ma, and P. Lipsky, “Cytokines and autoimmunity,” Nature Reviews Immunology, vol. 2, no. 1, pp. 37–45, 2002. View at Publisher · View at Google Scholar · View at Scopus
  2. J. K. Tarlow, A. I. F. Blakemore, A. Lennard et al., “Polymorphism in human IL-1 receptor antagonist gene intron 2 is caused by variable numbers of an 86-bp tandem repeat,” Human Genetics, vol. 91, no. 4, pp. 403–404, 1993. View at Google Scholar · View at Scopus
  3. M. Dale and M. J. H. Nicklin, “Interleukin-1 receptor cluster: gene organization of IL1R2, IL1R1 IL1RL2 (IL-1Rrp2), IL1RL1 (T1/ST2), and IL18R1 (IL-1Rrp) on human chromosome 2q,” Genomics, vol. 57, no. 1, pp. 177–179, 1999. View at Publisher · View at Google Scholar · View at Scopus
  4. D. M. Chang, “Interleukin-1 and interleukin-1 receptor antagonist in systemic lupus erythematosus,” Immunological Investigations, vol. 26, no. 5-7, pp. 649–659, 1997. View at Publisher · View at Google Scholar · View at Scopus
  5. G. S. Baird and T. J. Montine, “Multiplex immunoassay analysis of cytokines in idiopathic inflammatory myopathy,” Archives of Pathology & Laboratory Medicine, vol. 132, no. 2, pp. 232–238, 2008. View at Google Scholar · View at Scopus
  6. C. Gabay, F. Gay-Croisier, P. Roux-Lombard et al., “Elevated serum levels of interleukin-1 receptor antagonist in polymyositis/dermatomyositis: a biologic marker of disease activity with a possible role in the lack of acute-phase protein response,” Arthritis and Rheumatism, vol. 37, no. 12, pp. 1744–1751, 1994. View at Publisher · View at Google Scholar · View at Scopus
  7. B. Brugos, E. Kiss, C. Dul et al., “Measurement of interleukin-1 receptor antagonist in patients with systemic lupus erythematosus could predict renal manifestation of the disease,” Human Immunology, vol. 71, no. 9, pp. 874–877, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. K. Son, Y. Tomita, T. Shimizu, S. Nishinarita, S. Sawada, and T. Horie, “Abnormal IL-1 receptor antagonist production in patients with polymyositis and dermatomyositis,” Internal Medicine, vol. 39, no. 2, pp. 128–135, 2000. View at Publisher · View at Google Scholar · View at Scopus
  9. A. M. Prieur, A. Dayer, P. Roux-Lombard, and J. M. Dayer, “Levels of cytokine inhibitors: a possible marker of disease activity in childhood dermatomyositis and polymyositis,” Clinical and Experimental Rheumatology, vol. 15, no. 2, pp. 211–214, 1997. View at Google Scholar · View at Scopus
  10. A. Bohan and J. B. Peter, “Polymyositis and dermatomyositis,” The New England Journal of Medicine, vol. 292, no. 7, pp. 344–347, 1975. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Bohan and J. B. Peter, “Polymyositis and dermatomyositis II,” The New England Journal of Medicine, vol. 292, no. 8, pp. 403–407, 1975. View at Publisher · View at Google Scholar · View at Scopus
  12. I. N. Targoff, F. W. Miller, T. A. Medsger Jr., and C. V. Oddis, “Classification criteria for the idiopathic inflammatory myopathies,” Current Opinion in Rheumatology, vol. 9, no. 6, pp. 527–535, 1997. View at Google Scholar · View at Scopus
  13. S. S. Witkin, S. Gerber, and W. J. Ledger, “Influence of interleukin-1 receptor antagonist gene polymorphism on disease,” Clinical Infectious Diseases, vol. 34, no. 2, pp. 204–209, 2002. View at Publisher · View at Google Scholar · View at Scopus
  14. A. I. F. Blakemore, J. K. Tarlow, M. J. Cork, C. Gordon, P. Emery, and G. W. Duff, “Interleukin-1 receptor antagonist gene polymorphism as a disease severity factor in systemic lupus erythematosus,” Arthritis and Rheumatism, vol. 37, no. 9, pp. 1380–1385, 1994. View at Publisher · View at Google Scholar · View at Scopus
  15. H. Suzuki, Y. Matsui, and H. Kashiwagi, “Interleukin-1 receptor antagonist gene polymorphism in Japanese patients with systemic lupus erythematosus,” Arthritis & Rheumatism, vol. 40, no. 2, pp. 389–390, 1997. View at Publisher · View at Google Scholar · View at Scopus
  16. C.-M. Huang, M.-C. Wu, J.-Y. Wu, and F.-J. Tsai, “Interleukin-1 receptor antagonist gene polymorphism in Chinese patients with systemic lupus erythematosus,” Clinical Rheumatology, vol. 21, no. 3, pp. 255–257, 2002. View at Publisher · View at Google Scholar · View at Scopus
  17. C. G. Parks, G. S. Cooper, M. A. Dooley et al., “Systemic lupus erythematosus and genetic variation in the interleukin 1 gene cluster: a population based study in the southeastern United States,” Annals of the Rheumatic Diseases, vol. 63, no. 1, pp. 91–94, 2004. View at Publisher · View at Google Scholar · View at Scopus
  18. F. Tjernström, G. Hellmer, O. Nived, L. Truedsson, and G. Sturfelt, “Synergetic effect between interleukin-1 receptor antagonist allele (IL1RN*2) and MHC class II (DR17,DQ2) in determining susceptibility to systemic lupus erythematosus,” Lupus, vol. 8, no. 2, pp. 103–108, 1999. View at Publisher · View at Google Scholar · View at Scopus
  19. G. G. Song, J. H. Kim, Y. H. Seo, S. J. Choi, J. D. Ji, and Y. H. Lee, “Associations between interleukin 1 polymorphisms and susceptibility to systemic lupus erythematosus: a meta-analysis,” Human Immunology, vol. 75, no. 1, pp. 105–112, 2014. View at Google Scholar
  20. T. P. Lau, L. H. Lian, S. Y. Tan, and K. H. Chua, “VNTR polymorphisms of the IF-1RN gene: IL-1RN1 allele and the susceptibility of SLE in the Malaysian population,” International Journal of Biomedical and Pharmaceutical Sciences, vol. 2, no. 1, pp. 32–37, 2009. View at Google Scholar
  21. J. Heward, A. Allahabadia, C. Gordon et al., “The interleukin-1 receptor antagonist gene shows no allelic association with three autoimmune diseases,” Thyroid, vol. 9, no. 6, pp. 627–628, 1999. View at Publisher · View at Google Scholar · View at Scopus
  22. S. D'Alfonso, M. Rampi, D. Bocchio, G. Colombo, R. Scorza-Smeraldi, and P. Momigliano-Richardi, “Systemic lupus erythematosus candidate genes in the Italian population: evidence for a significant association with interleukin-10,” Arthritis & Rheumatism, vol. 43, no. 1, pp. 120–128, 2000. View at Google Scholar
  23. V. A. Danis, M. Millington, Q. Huang, V. Hyland, and D. Grennan, “Lack of association between an interleukin-1 receptor antagonist gene polymorphism and systemic lupus erythematosus,” Disease Markers, vol. 12, no. 2, pp. 135–139, 1995. View at Google Scholar · View at Scopus
  24. M. Mohammadoo-Khorasani, S. Salimi, E. Tabatabai, M. Sandoughi, and Z. Zakeri, “Association of interleukin-1 receptor antagonist gene 86bp VNTR polymorphism with systemic lupus erythematosus in south east of Iran,” Zahedan Journal of Research in Medical Sciences, vol. 16, no. 12, pp. 51–54, 2014. View at Google Scholar
  25. P. K. Manchanda, H. K. Bid, and R. D. Mittal, “Ethnicity greatly influences the interleukin-1 gene cluster(IL-1b promoter, exon-5 and IL-1Ra) polymorphisms: a pilot study of a north Indian population,” Asian Pacific Journal of Cancer Prevention, vol. 6, no. 4, pp. 541–546, 2005. View at Google Scholar · View at Scopus
  26. A. Jönsen, A. A. Bengtsson, G. Sturfelt, and L. Truedsson, “Analysis of HLA DR, HLA DQ, C4A, FcgammaRIIa, FcgammaRIIIa, MBL, and IL-1Ra allelic variants in Caucasian systemic lupus erythematosus patients suggests an effect of the combined FcgammaRIIa R/R and IL-1Ra 2/2 genotypes on disease susceptibility.,” Arthritis research & therapy., vol. 6, no. 6, pp. R557–562, 2004. View at Publisher · View at Google Scholar · View at Scopus
  27. N. J. Camp, A. Cox, F. S. di Giovine, D. McCabe, W. Rich, and G. W. Duff, “Evidence of a pharmacogenomic response to interleukin-1 receptor antagonist in rheumatoid arthritis,” Genes and Immunity, vol. 6, no. 6, pp. 467–471, 2005. View at Publisher · View at Google Scholar · View at Scopus
  28. L. G. Rider, C. M. Artlett, C. B. Foster et al., “Polymorphisms in the IL-1 receptor antagonist gene VNTR are possible risk factors for juvenile idiopathic inflammatory myopathies,” Clinical & Experimental Immunology, vol. 121, no. 1, pp. 47–52, 2000. View at Publisher · View at Google Scholar · View at Scopus